The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Halozyme Therapeutics's share price is $38.57.
Halozyme Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $6.20. Hence, Halozyme Therapeutics's PS Ratio for today is 6.22.
The historical rank and industry rank for Halozyme Therapeutics's PS Ratio or its related term are showing as below:
HALO'
s PS Ratio Range Over the Past 10 Years
Min: 5.43 Med: 13.4 Max: 35.11
Current: 6.22
During the past 13 years, Halozyme Therapeutics's highest PS Ratio was 35.11. The lowest was 5.43. And the median was 13.40.
HALO's PS Ratio is ranked better than 60.79% of 992
companies
in the Biotechnology industry
Industry Median: 8.85
vs HALO: 6.22
During the past 12 months, the average Revenue per Share Growth Rate of Halozyme Therapeutics was 31.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 48.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 45.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 24.90% per year.
During the past 13 years, Halozyme Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 232.20% per year. The lowest was -6.00% per year. And the median was 41.60% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Halozyme Therapeutics's PS Ratio
For the Biotechnology subindustry, Halozyme Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's PS Ratio falls into.
Halozyme Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Halozyme Therapeutics's Share Price of today is $38.57. Halozyme Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Halozyme Therapeutics (NAS:HALO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Halozyme Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics (Halozyme Therapeutics) Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your 